$BRVE 4 SEC Filings

Filed On	Filing
11 Aug 2026	Form 4: Ah Bio Fund IV, L.p., 10% owner and 3 others Received 9,132,420 shares by conversion · Bought 1,100,000 shares ($19.8M)
11 Aug 2026	Form 4: Chimovits Erez, Director Received 9,132,420 shares by conversion · Bought 1,940,000 shares ($34.9M)
11 Aug 2026	Form 4: Orbimed Advisors Llc, Director and 2 others Received 9,132,420 shares by conversion · Bought 1,940,000 shares ($34.9M)
10 Aug 2026	Form 4: Jiangsu Hengrui Pharmaceuticals Co., Ltd., 10% owner Received 7,420,091 shares by conversion
07 Aug 2026	Form 4: Forbion Growth Opportunities Fund Iii Cooperatief U.a., 10% owner and 3 others Received 17,123,287 shares by conversion · Bought 3,600,000 shares ($64.8M)
07 Aug 2026	Form 4: Rickey James Paul, Chief Financial Officer Granted 300,000 Stock Option (Right to Buy) · Bought 27,777 shares ($500K)
07 Aug 2026	Form 4: Lohoff Tim, Director Granted 30,000 Stock Option (Right to Buy)
07 Aug 2026	Form 4: Chimovits Erez, Director Granted 30,000 Stock Option (Right to Buy)
07 Aug 2026	Form 4: Viehbacher Christopher, Director Granted 30,000 Stock Option (Right to Buy) · Bought 83,333 shares ($1.5M)
07 Aug 2026	Form 4: Malek David I, Director Granted 30,000 Stock Option (Right to Buy) · Bought 4,166 shares ($75K)
07 Aug 2026	Form 4: Anderson Michele A., Chief Development Officer Granted 300,000 Stock Option (Right to Buy) · Bought 1,111 shares ($20K)
07 Aug 2026	Form 4: Murdoch Travis, Director Granted 550,000 Stock Option (Right to Buy) · Bought 83,333 shares ($1.5M)
07 Aug 2026	Form 4: Bos Jasper, Director Granted 30,000 Stock Option (Right to Buy)
07 Aug 2026	Form 4: Lubner David Charles, Director Granted 60,000 Stock Option (Right to Buy) · Bought 55,555 shares ($1M)

Comments